Ecotrophelia Switzerland 2026 brought...
EraCal Therapeutics, the Biotech Company Developing Solutions to Different Diseases, Joins SFNV
EraCal Therapeutics, the Biotech Company Developing Solutions to Different Diseases, Joins SFNV
The preclinical biotech startup, EraCal Therapeutics, which develops drugs using cutting-edge science to treat health and obesity issues, has joined the SFNV.
Switzerland, February 2021 – EraCal Therapeutics, a Swiss producer of biotechnology drugs using cutting-edge technology to treat metabolic syndrome, has joined the SFNV. The company is currently focusing on a pipeline of appetite suppressants to tackle obesity and its metabolic complications. Its lead molecule, Era-107, is an oral appetite suppressor with superior efficacy and safety profile, as demonstrated in three vertebrate species. EraCal is now preparing to carry out further toxicology studies ahead of first-in-human trials.
For more information:
E-mail : info@eracal.ch
Latest Members
Swiss student innovators took the stage at Ecotrophelia Switzerland 2026
planetary raises ~$28 million (CHF 22 million) in funding to scale global fermentation infrastructure and licensing platform
Planetary SA (“planetary” or the...
Healthy eating – can we close the gap between evidence and public belief?
Healthy eating – can we closethe gap...








